Compare GXO Logistics Inc (GXO) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GXO Logistics Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? GXO Logistics Inc trades at $46.47 (market cap $5.32B), while Vertex Pharmaceuticals Incorporated trades at $510.07 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 24× GXO Logistics Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, GXO Logistics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GXO Logistics Inc for 28 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| GXO | VRTX | |
|---|---|---|
Market Cap | $5.32B | $127.55B |
Volume | 1,255,816 | 1,487,944 |
Sector | Industrials | Health |
52-Week High | $65.59 | $557.96 |
52-Week Low | $44.17 | $407.37 |
Typical Hold Time | 28 Days | 120 Days |
Enterprise Value | $10.67B | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GXO trades at $46.58, up 1.28% today, with a neutral technical signal and strong analyst support. The company reported three consecutive quarterly EPS beats and is expanding through strategic partnerships, including a new 10-year logistics deal with Columbia Sportswear in Europe. Revenue grew to $13.18B in 2025, with a net income margin of 0.96%, though valuation metrics like a P/E of 41.03 appear elevated relative to profitability.
The outlook is positive, driven by operational improvements and industry tailwinds, but risks include margin pressures and high debt. With an 89% buy rating from analysts and a consensus price target of $66.67, the stock offers significant upside potential if execution aligns with growth initiatives.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GXO Logistics Inc
GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.
Read more on GXO →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
